This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may slow down how quickly your liver processes flibanserin or lomitapide.
What might happen:
The amount of flibanserin or lomitapide in your blood may increase and cause more side effects than normally expected.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know as soon as possible that you are taking these medicines together. Your doctor may want to discontinue or adjust the dose of your lomitapide, or discontinue flibanserin while you are taking your other medicine.If you are taking flibanserin and feel lightheaded or dizzy, lie down right away. Get emergency medical help if the symptoms don't get better or if you feel like you might faint (lose consciousness).If you are taking lomitapide, let your doctor know right away if you have any pain or discomfort in the upper right stomach (abdominal) area, yellowing of the skin or eyes, loss of appetite, nausea or vomiting, fever or dark/amber-colored urine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Juxtapid (lomitapide) US prescribing information. Aegerion Pharmaceuticals, Inc. March, 2016.
2.Addyi (flibanserin) US prescribing information. Sprout Pharmaceuticals August, 2015.
3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
4.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..